Perimenopausal Disorder

3

Review clinical trials related to Perimenopausal Disorder. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Multimodal Program for Climacteric Women

Your study seems to aim at emphasizing the significance of non-pharmacological and non-hormonal approaches in managing menopausal symptoms, particularly focusing on muscle training and education. This holistic approach acknowledges the importance of physical well-being, psychological support, and education to enhance women's quality of life during the menopausal transition.

Participants needed: 115
Trial details
Age: 45-85Biological sex: FemaleType: InterventionalSponsor: University of ValenciaUpdated: May 19, 2026Locations: 2
Eligibility criteria

Women aged ≥45 years [+1]

Musculoskeletal, cognitive, infectious, neurological, or cardiorespiratory patho... [+1]

Status: Recruiting

The MUSE Study for Menopausal Arthralgia

The investigators plan to conduct a pilot 4-arm, randomized study comprising the following interventions: muscle strengthening exercises (MSE) alone, estrogen therapy (ET) alone, and a combination of MSE and ET, compared to usual care in women with menopausal arthralgia. The aim of this pilot study is to assess the feasibility, patient acceptability, and patient perspectives and logistics of delivering interventions, and practicability of outcome assessment tools in this 4-arm study over a 12-week period.

Participants needed: 100
Trial details
Phase: Phase 2, Phase 3Age: 30-59Biological sex: FemaleType: InterventionalSponsor: National University Hospital, SingaporeUpdated: Jul 31, 2024Locations: 1
Eligibility criteria

Patients with muscle stiffness and joint discomfort in various sites, including... [+4]

History of thrombo-embolic diseases, strokes, ischemic heart disease, dementia o... [+15]

Status: Recruiting

Virtual perI-/Menopause Registry of AusTrALia

13 million (50.7%) Australians are born with ovaries, 14% (\~3 million) are currently aged 40-59 yrs, \& all such who live to midlife will experience menopause, defined as \>12 months without a period. Peri-menopause (peri), typically occurs 5 yrs before menopause as hormone levels decrease. As with oestrogen, peri symptoms can affect every bodily system; e.g. depression/anxiety, diminished mental function, irregular periods, hot flushes, sleep problems, vaginal atrophy \& urinary urgency. These symptoms are linked with lower quality of life \& significantly higher work impairment; a third experiencing symptoms so severe as to impede daily life \& increase risk of suicide. Lifetime increased risks of diabetes, heart disease, osteoporosis \& dementia are also associated with menopause, yet it remains disconcertingly poorly studied. The investigators propose to create a world-first, cutting-edge, consumer-driven, Virtual peri-/menopause registry of AusTrALia (VITAL). The unique design will enable consumers to determine VITAL's questions, encourage secure revelation of private data e.g. vaginal \& mental health symptoms, \& to direct priorities for research, education, \& health service improvements. VITAL will thus deliver optimal assessments of incidence, prevalence \& impact. The participating consumers, researchers, clinical specialists, policy makers, \& modern virtual data infrastructure enable this unique \& innovative registry design, future translation to improved community health, \& promote awareness \& collaborative synergies. Leveraging the investigators' critical range of expertise \& ongoing feedback opportunities for both participants \& stakeholder partnerships, the investigators will create a ground-breaking platform that: * empowers the consumer voice and priorities, * enables peri-/menopause research to extend beyond existing niche focuses, * evidences the true impact of peri-/menopause across the nation, * evolves healthcare services and outcomes, \& * educates community, clinicians, \& policy-makers. After Australian registry establishment, the investigators will expand VITAL to mirror it in other nations while still protecting individual's data the right way, but so all can learn \& apply the best aspects of care from across the world.

Participants needed: 10,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Bespoke Clinical ResearchUpdated: Jul 5, 2024Locations: 1Duration: 50 Years
Eligibility criteria

Any Australian over 18 years of age.

None.